Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 22;8(38):64217-64223.
doi: 10.18632/oncotarget.19450. eCollection 2017 Sep 8.

Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease

Hai-Chen Lv #  1 , Hong-Yi Wu #  2 , Jia-Sheng Yin  2 , Jun-Bo Ge  2
Affiliations

Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease

Hai-Chen Lv et al. Oncotarget. .

Abstract

Platelet aggregation and inflammation are both implicated in coronary artery disease (CAD). Thrombin induced platelet-fibrin clot strength (MAThrombin) measured by thrombelastography (TEG) has been proved to be a novel marker of platelet aggregation. The aim of this study was to investigate the correlation of MAThrombin to platelet volume indices (PVIs) or to inflammatory markers in different types of CAD. 206 patients with different types of CAD were enrolled. MAThrombin, PVIs, including mean platelet volume (MPV), platelet distribution width (PDW), and platelet-large cell ratio (P-LCR) as well as inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP) and fibrinogen (Fbg) were measured. Multiple linear regression models were used to analyze the association between MAThrombin, PVIs, and inflammatory markers. MAThrombin and inflammatory markers both varied with CAD types (P<0.001). MAThrombin was correlated to PVIs in NSTEMI individuals (MPV, r=0.393, P=0.007; PDW, r=0.334, P=0.023; P-LCR, r=0.382, P=0.008), but had inner-link with inflammatory markers in STEMI cases (hs-CRP, r=0.499, P<0.001; Fbg, r=0.500, P<0.001). These findings may suggest different mechanisms of platelet aggregation in different types of CAD. Moreover, MAThrombin may be used as a potential parameter to evaluate platelet aggregation and inflammation together.

Keywords: coronary artery disease; inflammatory marker; platelet activation; platelet volume index; thrombelastography.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no competing financial interests.

References

    1. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549–1554. - PubMed
    1. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood. 2010;116:2627–2634. - PMC - PubMed
    1. Priebe HJ. Perioperative myocardial infarction—aetiology and prevention. Br J Anaesth. 2005;95:3–19. - PubMed
    1. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–2051. - PMC - PubMed
    1. Wu H, Qian J, Wang Q, Lv H, Sun A, Ge J. Thrombin induced platelet-fibrin clot strength measured by thrombelastography is a novel marker of platelet activation in acute myocardial infarction. Int J Cardiol. 2014;172:e24–e25. - PubMed